ARTICLE | Deals
Imcyse moves closer to next financing round with Pfizer RA deal
February 3, 2021 10:10 PM UTC
A new partnership with Pfizer for its RA program gets Imcyse another step closer to raising its next round of financing that would support clinical trials of its pipeline through at least 2023.
On Wednesday Pfizer Inc. (NYSE:PFE) exercised its option to license worldwide rights to the Belgian biotech’s preclinical Imotope program targeting rheumatoid arthritis. Imcyse S.A. will receive an undisclosed upfront payment and Pfizer will make an equity investment in the biotech’s next financing round. In addition, Imcyse is eligible for up to $180 million in milestones, plus royalties. ...